Lifevantage Corp SEC filings LFVN
Lifevantage Corp has 1,001 filings in SEC EDGAR's recent list, going back to Oct 28, 2009. Its latest annual report, Form ARS, was filed on Sep 18, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 6, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 5, 2026 (bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Sep 18, 2026 | — |
| DEF 14A | Proxy statement | Sep 18, 2026 | Nov 5, 2026 |
| DEFA14A | Additional proxy material | Sep 19, 2025 | — |
| DEF 14A | Proxy statement | Sep 19, 2025 | Sep 19, 2025 |
| DEFA14A | Additional proxy material | Sep 20, 2024 | — |
| DEF 14A | Proxy statement | Sep 20, 2024 | Sep 20, 2024 |
| DEFA14A | Additional proxy material | Oct 30, 2023 | — |
| DEFA14A | Additional proxy material | Oct 25, 2023 | — |
| DEFA14A | Additional proxy material | Oct 18, 2023 | — |
| DEFA14A | Additional proxy material | Oct 16, 2023 | — |
| DEFA14A | Additional proxy material | Oct 16, 2023 | — |
| DEFA14A | Additional proxy material | Oct 13, 2023 | — |
| DEFA14A | Additional proxy material | Oct 10, 2023 | — |
| DEFA14A | Additional proxy material | Oct 10, 2023 | — |
| DEFA14A | Additional proxy material | Oct 5, 2023 | — |
| DEFA14A | Additional proxy material | Oct 2, 2023 | — |
| DEFA14A | Additional proxy material | Sep 25, 2023 | — |
| DEFA14A | Additional proxy material | Aug 14, 2023 | — |
| DEFA14A | Additional proxy material | Sep 30, 2022 | — |
| DEF 14A | Proxy statement | Sep 30, 2022 | Sep 16, 2022 |
| DEFA14A | Additional proxy material | Sep 30, 2021 | — |
| DEF 14A | Proxy statement | Sep 30, 2021 | Sep 17, 2021 |
| DEFA14A | Additional proxy material | Nov 4, 2020 | — |
| DEFA14A | Additional proxy material | Sep 30, 2020 | — |
| DEF 14A | Proxy statement | Sep 30, 2020 | Sep 18, 2020 |
| DEFA14A | Additional proxy material | Nov 26, 2019 | — |
| DEFA14A | Additional proxy material | Oct 18, 2019 | — |
| DEF 14A | Proxy statement | Oct 18, 2019 | Oct 10, 2019 |
| DEFA14A | Additional proxy material | Sep 28, 2018 | — |
| DEF 14A | Proxy statement | Sep 28, 2018 | Sep 28, 2018 |
| DEFA14A | Additional proxy material | Jan 26, 2018 | — |
| DEFA14A | Additional proxy material | Jan 23, 2018 | — |
| DEFA14A | Additional proxy material | Dec 20, 2017 | — |
| DEF 14A | Proxy statement | Dec 20, 2017 | Dec 20, 2017 |
| PRE 14A | Preliminary proxy statement | Nov 28, 2017 | Nov 28, 2017 |
| DEFA14A | Additional proxy material | Feb 3, 2017 | — |
| DEF 14A | Proxy statement | Jan 4, 2017 | Jan 4, 2017 |
| DEF 14A | Proxy statement | Sep 11, 2015 | Oct 15, 2015 |
| DEFA14A | Additional proxy material | Sep 2, 2015 | — |
| PRE 14A | Preliminary proxy statement | Sep 1, 2015 | Oct 15, 2015 |
| DEF 14A | Proxy statement | Sep 1, 2015 | Oct 15, 2015 |
| DEF 14A | Proxy statement | Oct 6, 2014 | Nov 19, 2014 |
| DEF 14A | Proxy statement | Sep 27, 2013 | Nov 13, 2013 |
| DEFA14A | Additional proxy material | Nov 6, 2012 | — |
| DEF 14A | Proxy statement | Oct 9, 2012 | Nov 14, 2012 |
| DEF 14A | Proxy statement | Nov 14, 2011 | Jan 10, 2012 |
| DEF 14A | Proxy statement | Oct 4, 2010 | Nov 19, 2010 |
| DEF 14A | Proxy statement | Oct 28, 2009 | Jan 15, 2010 |
Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LFVN (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Lehi, UT
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 849146
- Former names
- LIFELINE THERAPEUTICS, INC. (until Dec 6, 2006); YAAK RIVER RESOURCES INC (until Sep 28, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.